Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy with Panitumumab or Bevacizumab in Cholangiocarcinoma
NCT01206049Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Sep 2010
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cholangiocarcinoma (CCA) comparing Chemo + Panitumumab with Chemo + Bevacizumab (2 arms). Primary endpoint: Progression-Free Survival Rate at 6 months. Started Sep 2010; status: completed.
02
Drugs
panitumumabbevacizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT01206049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206049.